Novartis Closes Morphosys, Affecting Hundreds of Jobs

Nearly 330 jobs are on the chopping block as Novartis moves to dismantle the physical operations of Morphosys just months after acquiring it. In a decisive and ruthless move, the Basel-based pharmaceutical titan confirmed it will shutter all Morphosys sites in Germany and the United States by the end of 2025. This closure comes as a shockwave to the European biotech sector, marking the end of the road for a company that was once a pillar of German innovation. Novartis paid a staggering €2.7 billion (CHF 2.5 billion) for the firm earlier this year, a massive investment that is now being aggressively consolidated. While the intellectual property and portfolio activities will be absorbed into the Novartis machine, the physical legacy of Morphosys—founded in 1992—is being erased. The speed of this dissolution underscores the volatile nature of big pharma acquisitions, where operational redundancies are swiftly eliminated in the pursuit of efficiency.

An eye-watering $800 million vanished from the books recently as Novartis was forced to re-assess the true value of its acquisition. This dramatic write-down serves as a stark admission that the initial valuation of Morphosys was overly optimistic. The financial correction highlights the perilous landscape of pharmaceutical M&A, where potential blockbusters can quickly turn into liabilities. Novartis CEO Vas Narasimhan has consistently championed a strategy of focused acquisitions, but this massive adjustment suggests that the due diligence may have missed critical red flags. The company is now grappling with the reality that a significant portion of the asset's perceived value has evaporated. While Novartis maintains that its broader strategy is 'bearing fruit,' this specific financial hit is a bruised apple in the basket, raising uncomfortable questions about the precision of their recent spending spree.

The crown jewel of the acquisition, a drug named Pelabresib, has lost its shine. Novartis bought Morphosys primarily to gain access to this treatment for myelofibrosis, a potentially fatal chronic bone marrow disease. However, recent data has cast a long shadow over the drug's future. Serious concerns regarding both efficacy and safety have emerged, forcing the re-evaluation that triggered the financial write-down. What was billed as a breakthrough therapy is now confronting the harsh realities of clinical scrutiny. The Basel giant is not abandoning the drug entirely but is integrating the development into its own rigorous systems. Nevertheless, the optimism that drove the multi-billion franc purchase has been tempered by clinical data that failed to meet the high bar set for a game-changing oncology treatment. This situation exemplifies the high-risk gamble of buying clinical-stage biotechs: the science does not always cooperate with the business plan.